首页> 外文期刊>Organic process research & development >Use of Enzymes in the Manufacture of Active Pharmaceutical Ingredients桝 Science and Safety-Based Approach To Ensure Patient Safety and Drug Quality
【24h】

Use of Enzymes in the Manufacture of Active Pharmaceutical Ingredients桝 Science and Safety-Based Approach To Ensure Patient Safety and Drug Quality

机译:在活性药物成分生产中使用酶的科学和基于安全性的方法可确保患者安全和药物质量

获取原文
获取原文并翻译 | 示例
           

摘要

A significant number of marketed pharmaceuticals contain active pharmaceutical ingredients that are manufactured in part using biocatalysis as a key enabling technology. The utilization of biocatalysis is growing due to significant advances in technologies for enzyme discovery, supply, and improvement, as well as an increased focus on applications for chiral drugs and green chemistry. Nevertheless, there still remains a lack of clarity around quality and regulatory expectations when using biotransformations in research and manufacturing, and this lack of clarity can be a barrier to the uptake and adoption of biocatalysis. This commentary will explore and offer some rational, coherent, and achievable strategies for the use of biocatalysis in the manufacture of small molecule active pharmaceutical ingredients (APIs) based on a scientific, risk-based approach to drug quality and patient safety. We also seek to invite other interested parties to contact us with their views to add to the topics discussed here with the goal of expanding these thoughts into an industry-based white paper.
机译:大量上市的药物都含有活性药物成分,这些成分部分是利用生物催化作为关键的使能技术制造的。由于酶的发现,供应和改进技术的重大进步,以及对手性药物和绿色化学应用的日益关注,生物催化的利用正在增长。然而,在研究和制造中使用生物转化时,在质量和法规要求方面仍然缺乏明确性,并且这种缺乏明确性可能成为吸收和采用生物催化的障碍。本评论将探索和提供一些合理,连贯和可实现的策略,以基于科学,基于风险的药物质量和患者安全性方法在小分子活性药物成分(API)的生产中使用生物催化。我们还力图邀请其他感兴趣的各方与我们联系,以他们的观点来补充此处讨论的主题,以将这些思想扩展为基于行业的白皮书。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号